The EVICEL® Neurosurgery Phase III Study


The objective of this study is to evaluate the safety and efficacy of EVICEL® Fibrin Sealant (Human) for use as an adjunct to sutured dural repair in cranial surgery.

Study Start Date

July 2015

Estimated Completion Date

February 2017


  • Device: Hydrogel sealant
  • Biological: EVICEL Fibrin Sealant


  • Surgery: Neurosurgery
  • Neurology: Neurosurgery
  • Physician Assistant: Neurology

MeSH Terms

  • Cerebrospinal Fluid Leak
  • Cerebrospinal Fluid Rhinorrhea
  • Craniocerebral Trauma
  • Wounds and Injuries

Study ID

Ethicon, Inc. -- BIOS-14-002



Trial ID


Study Type


Trial Phase

Phase 3

Enrollment Quota



Ethicon, Inc.

Inclusion Criteria

  • Subjects ?18 years of age undergoing craniotomy/craniectomy for pathological processes in the supratentorial region or posterior fossa
  • Subjects or legally authorized representatives must be willing to participate in the study and provide written informed consent.
  • Surgical wound classification Class I
  • The cuff of native dura along the craniotomy edge on each side is adequate, based on surgeon's judgment, to facilitate suturing and to allow for sufficient surface area for adherence of the investigational product
  • Presence of intra-operative cerebrospinal fluid (CSF) leakage following primary dural closure or after Valsalva maneuver

Exclusion Criteria

  • Subjects with a dural lesion from a recent surgery that still has the potential for CSF leakage.
  • Chemotherapy scheduled within 7 days following surgery.
  • Radiation therapy to the head scheduled within 7 days following surgery.
  • A previous craniotomy/craniectomy within 6 months prior to the study surgery.
  • Known hypersensitivity to the components of the investigational product.
  • Subjects with a known allergy to FD&C Blue #1 dye
  • Subjects with an infection present at the surgical site
  • Subjects with an infection indicated by any one of the following: clinical diagnosis of infection, fever, positive urine culture, positive blood culture, positive chest X-ray.
  • Female subjects of childbearing potential with a positive pregnancy test or intent to become pregnant during the clinical study period.
  • Female subjects who are nursing.
  • Exposure to another investigational drug or device clinical trial within 30 days prior to enrollment or anticipated in the 60 day follow-up period.
  • Subjects with severely altered renal or hepatic function, with a compromised immune system or autoimmune disease who can NOT receive hydrogel sealant.
  • Subjects with traumatic injuries to the head
  • Dural injury during craniotomy/craniectomy that cannot be eliminated by widening the craniotomy/craniectomy to recreate the native dural cuff.
  • Patient has a gap between durotomy edges of greater than 2mm after primary dural closure.
  • Approaches that would not allow sutured dural closure such as trans-sphenoidal or trans-labirinthine-/petrosal/-mastoid. Superficial penetration of mastoid air cells are allowed.
  • Use of implants made of synthetic materials coming into direct contact with dura
  • Use of other fibrin sealants or PEG-based sealants.
  • Hydrocephalus, except occlusive hydrocephalus caused by posterior fossa pathology or incompletely open cerebrospinal fluid pathways, to be treated during surgical procedure.
  • Placement of Gliadel Wafers
  • Intersecting durotomy scars in the surgical path from a previous operation that cannot be completely removed by the planned dural resection.
  • Two or more separate dural defects
  • Subjects with any other intra-operative findings identified by the surgeon that may preclude the conduct of the study procedure.
  • Confined bony structures where nerves are present where neural compression may result due to swelling.




18 Years and older

Accepts Healthy Volunteers


Study Locations and Contact Information (13)

Study Location Distance Name Phone Email
Clinical Investigation Site 11 - Boston, Massachusetts 2.4 miles None None None
Clinical Investigation Site 12 - New York, New York 187.1 miles None None None
Clinical Investigation Site 20 - New Brunswick, New Jersey 216.0 miles None None None
Clinical Investigation Site 21 - Philadelphia, Pennsylvania 269.5 miles None None None
Clinical Investigation Site 15 - Baltimore, Maryland 358.9 miles None None None
Clinical Investigation Site 24 - Ann Arbor, Michigan 645.2 miles None None None
Clinical Investigation Site 14 - Cincinnati, Ohio 737.9 miles None None None
Clinical Investigation Site 22 - Indianapolis, Indiana 805.0 miles None None None
Clinical Investigation Site 18 - Jacksonville, Florida 1,020.2 miles None None None
Clinical Investigation Site 16 - Stuart, Florida 1,170.8 miles None None None
Clinical Investigation Site 19 - Tampa, Florida 1,186.3 miles None None None
Clinical Investigation Site 10 - New Orleans, Louisiana 1,363.3 miles None None None
Clinical Investigation Site 17 - Sacramento, California 2,628.4 miles None None None provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.